A hot ingredient topic right now for individuals interested in healthspan, mushrooms are emerging as a promising source of bioactives that support key cellular pathways linked to healthy ageing, particularly when those bioactives are reliably standardised and traceable.
Rather than focusing on chronological age, consumers driven by healthspan – more years with better health – seek to boost cognitive health, reduce inflammation and support cellular and metabolic resilience. These are all areas where mushroom bioactives are actively being researched and increasingly positioned as functional ingredients.
The market is responding – longevity is already big business and only set to grow. The global functional mushroom market size was valued at $31.7bn in 2023 and is expected to grow at a CAGR of 11.2% from 2024 to 2030. North America is currently the largest market, accounting for around 45% of total revenue.1
Functional mushrooms are used across functional food and drink, as well as in dietary supplement formats including capsules, powders and tinctures, as well as infused products like coffee and teas reinforcing the need for higher quality, standardised ingredient solutions as the category matures.
Longevity science centres around several key biological mechanisms associated with ageing. These include mitochondrial function, stem cell and cellular regeneration, chronic inflammation and oxidative stress and studies are uncovering where mushroom bioactives may confer benefits.
Mitochondrial function
Mitochondria convert nutrients from food into energy and control how efficient this process is. When mitochondrial efficiency declines and oxidative stress rises, these changes are associated with fatigue, metabolic dysfunction and ageing. Several compounds found in mushroom species are being studied for their influence on pathways linked to mitochondrial efficiency and cellular energy production.
Stem cell and cellular regeneration
Healthy ageing depends on the body’s ability to repair tissues and maintain ongoing cellular regeneration. Research into mushroom-derived bioactive compounds is exploring their interaction with cellular signalling pathways related to regeneration and immune balance.
Chronic inflammation and oxidative stress
Low-grade inflammation and oxidative stress are often the hallmarks of ageing. Mushrooms such as Chaga (Inonotus obliquus) contain compounds including inotodiol and betulinic acids, and are considered a highly concentrated natural source of antioxidant compounds that are being studied for their biological activity in these areas.
Deep dive on Chaga
Chaga has gained interest in longevity research due to its rich profile of antioxidants and bioactive compounds including betulinic acid (frequently studied for oxidative stress modulation) and inotodiol, which has been investigated for immune-related biochemical pathways and cellular protection mechanisms. Its bioactives may also play a role in gut-immune crosstalk and metabolic and mitochondrial health.
Studies have explored its potential role in immune modulation, oxidative stress protection and cellular signalling pathways related to ageing.2
A small early-stage human trial, cited in a published paper, using NordRelease® Chaga extract powder, tested the efficacy of functional botanical ingredients for support of stem cell surveillance and mitochondrial resilience. It found that in a preliminary randomised, double-blind, placebo-controlled, acute clinical proof-of-concept trial, NordRelease® Chaga extract powder intake resulted in an average 36% increase in endothelial stem cells compared to placebo. In addition, the ingredient modulated stress-induced changes in mitochondrial volume and membrane potential.2
This preliminary study shows promising signals that a single dose of NordRelease® Chaga extract powder caused a short-term rise in certain stem cells and showed early signs of protecting mitochondria under stress. This may indicate potential biological activity in pathways relevant to cellular resilience. More comprehensive, long-term studies are needed to confirm the significance of these early indications.
Modern industry standards don’t match up
With the uptick in demand for functional mushroom ingredients, producers have been under pressure to scale in response but while volumes have increased, quality standards and analytical methods have not always kept pace.
Many suppliers and retailers rely primarily on the beta-glucan content of mushrooms as the primary or sole measurement of quality. These are beneficial soluble fibres found in many foods including mushrooms. However, they are also abundant in other food sources including grain which is often used in substrates for mycelium-on-grain production.
Crucially, beta glucans do not correlate with the species-specific bioactives that drive effects in functional mushrooms, for example betulinic acid and inotodiol in Chaga. Therefore, relying on this as a measurement can be misleading or insufficient when assessing extract quality. Mycelium-based products (especially FMG – fermented mycelial grain) can show high glucan levels while containing little to none of the actual mushroom bioactives responsible for functional effects, highlighting the need for bioactive specific standardisation beyond generic markers.
Finnish biotechnology company, KÄÄPÄ Biotech, is the leading European supplier of functional mushroom ingredients for nutraceutical innovation, particularly in the rapidly growing field of healthy ageing and longevity. It focuses on producing high-quality, traceable mushroom ingredients with verified, standardised bioactive levels that allow nutraceutical companies and researchers to explore the potential role of mushrooms in supporting cellular pathways linked to healthy ageing properties.
While many suppliers rely on generic markers such as beta-glucans, KÄÄPÄ Biotech drives towards bioactive‑specific standards for the industry. The company’s proprietary NordRelease® extraction system has been evaluated and validated by the European Food Safety Authority (EFSA), which has some of the world’s most stringent regulatory standards.
This process delivers measurable standardised and reproductible bioactive levels across batches, resulting in consistent potency across industrial-scale production, purity and measurable bioactive yield. For formulators, access to quantified bioactives is essential for replicable and compliant product development and this is KÄÄPÄ Biotech’s point of difference.
“We operate a vertically integrated ecosystem built on transparency, traceability and consistent quality, from forest cultivation to final extract. Our Chaga is harvested in the birch forests of Finnish Lapland, supported by our KÄÄPÄ Forest division, now the world’s largest Chaga cultivation network. By combining strict quality standards with an evidence-based approach, we deliver species-specific bioactives that enable more precise and reliable formulations,” says Alistair Hatch, chief marketing officer, KÄÄPÄ Biotech.
References
- SPINS, US, 2024 and Grand View Research. Functional Mushroom Market (2024-2030)
- Jensen, Gitte S.; et al. Methodology for testing the efficacy of functional botanical ingredients for support of stem cell surveillance and mitochondrial resilience. Functional Food Science. Vol. 6 No. 1 (2025): January 2026